There is a long conversation taking place these days about monoclonal antibodies against COVID-19. From a few biology courses I had a long time ago, I remember that the process of creating mAbs was a very complex and delicate one, with relatively small yields, something that contributed to the reduced availability and the high price of such treatments.
I wanted to ask because after my research I got even more confused and I couldn't conclude: what is the current, "modern" procedure of mAb production? What are the yields and eventually how logical is to expect a mAb treatment to become widely accessible? Especially though, when "common" mAb therapies like adalimumab and infliximab cost a few thousand euros/year.